MedTrace Logo

Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients

NCT03931954 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 794

Last updated 2021-01-29

No results posted yet for this study

Summary

The purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and asthma control, will also be studied.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Maarten beekman, MD · medical lead respiratory International

  • Monica Olmos, MD · Study delivery lead

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2020-11-26
Completion
2020-11-26

Countries

  • Argentina
  • Chile
  • Colombia
  • Costa Rica
  • Mexico
  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03931954 on ClinicalTrials.gov